1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (CHEM012500)

Record Information
Version1.0
Creation Date2016-05-19 03:56:56 UTC
Update Date2026-05-14 17:45:43 UTC
Accession NumberCHEM012500
Identification
Common Name1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-
ClassSmall Molecule
Description
A resveratrol in which the double bond has E configuration.
Contaminant Sources
  • Cosmetic Chemicals
  • FooDB Chemicals
  • HMDB Contaminants - Urine
  • HPV EPA Chemicals
  • ToxCast & Tox21 Chemicals
Contaminant TypeNot Available
Chemical Structure
MOLSDF3D SDFPDBSMILESInChI View 3D Structure
Synonyms
ValueSource
(e)-5-(2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediolChEBI
(e)-ResveratrolChEBI
3,4',5-StilbenetriolChEBI
3,4',5-Trihydroxy-trans-stilbeneChEBI
3,4',5-TrihydroxystilbeneChEBI
3,5,4'-TrihydroxystilbeneChEBI
5-[(e)-2-(4-Hydroxyphenyl)vinyl]benzene-1,3-diolChEBI
trans-ResveratrolKegg
SRT-501MeSH
trans ResveratrolMeSH
SRT 501MeSH
trans-3,4',5 - TrihydroxystilbeneHMDB
(E)-2-(3,5-Dihydroxyphenyl)-1-(4-hydroxyphenyl)etheneHMDB
(E)-3,4',5-TrihydroxystilbeneHMDB
(E)-3,4’,5-TrihydroxystilbeneHMDB
(E)-5-(p-Hydroxystyryl)resorcinolHMDB
3,4’,5-StilbenetriolHMDB
3,4’,5-Trihydroxy-trans-stilbeneHMDB
3,4’,5-TrihydroxystilbeneHMDB
5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediolHMDB
ResveratrolHMDB
trans-3,5,4'-TrihydroxystilbeneHMDB
trans-3,5,4’-TrihydroxystilbeneHMDB
(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediolPhytoBank
Chemical FormulaC14H12O3
Average Molecular Mass228.247 g/mol
Monoisotopic Mass228.079 g/mol
CAS Registry Number501-36-0
IUPAC Name5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
Traditional Nameresveratrol
SMILESOC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1
InChI IdentifierInChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
InChI KeyLUKBXSAWLPMMSZ-OWOJBTEDSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassStilbenes
Sub ClassNot Available
Direct ParentStilbenes
Alternative Parents
Substituents
  • Stilbene
  • Styrene
  • Resorcinol
  • 1-hydroxy-4-unsubstituted benzenoid
  • 1-hydroxy-2-unsubstituted benzenoid
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Organic oxygen compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Biological Properties
StatusDetected and Not Quantified
OriginNot Available
Cellular LocationsNot Available
Biofluid LocationsNot Available
Tissue LocationsNot Available
PathwaysNot Available
ApplicationsNot Available
Biological RolesNot Available
Chemical RolesNot Available
Physical Properties
StateNot Available
AppearanceNot Available
Experimental Properties
PropertyValue
Melting PointNot Available
Boiling PointNot Available
SolubilityNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.069 g/LALOGPS
logP2.57ALOGPS
logP3.4ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)8.49ChemAxon
pKa (Strongest Basic)-6.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 ŲChemAxon
Rotatable Bond Count2ChemAxon
Refractivity67.46 m³·mol⁻¹ChemAxon
Polarizability24.55 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Spectra
Spectra
Toxicity Profile
Route of ExposureNot Available
Mechanism of ToxicityNot Available
MetabolismNot Available
Toxicity ValuesNot Available
Lethal DoseNot Available
Carcinogenicity (IARC Classification)Not Available
Uses/SourcesNot Available
Minimum Risk LevelNot Available
Health EffectsNot Available
SymptomsNot Available
TreatmentNot Available
Concentrations
Not Available
External Links
DrugBank IDDB02709
HMDB IDHMDB0003747
FooDB IDFDB002451
Phenol Explorer ID592
KNApSAcK IDC00002903
BiGG IDNot Available
BioCyc IDCPD-83
METLIN IDNot Available
PDB IDNot Available
Wikipedia LinkResveratrol
Chemspider ID392875
ChEBI ID45713
PubChem Compound ID445154
Kegg Compound IDC03582
YMDB IDYMDB01780
ECMDB IDM2MDB004896
References
Synthesis ReferenceNot Available
MSDSNot Available
General References
1. https://www.ncbi.nlm.nih.gov/pubmed/?term=11408943
2. https://www.ncbi.nlm.nih.gov/pubmed/?term=11414688
3. https://www.ncbi.nlm.nih.gov/pubmed/?term=15492766
4. https://www.ncbi.nlm.nih.gov/pubmed/?term=18261608
5. https://www.ncbi.nlm.nih.gov/pubmed/?term=18616940
6. https://www.ncbi.nlm.nih.gov/pubmed/?term=18789672
7. https://www.ncbi.nlm.nih.gov/pubmed/?term=19046449
8. https://www.ncbi.nlm.nih.gov/pubmed/?term=19084917
9. https://www.ncbi.nlm.nih.gov/pubmed/?term=24345046
10. https://www.ncbi.nlm.nih.gov/pubmed/?term=24467639
11. https://www.ncbi.nlm.nih.gov/pubmed/?term=25172731
12. https://www.ncbi.nlm.nih.gov/pubmed/?term=25308653
13. https://www.ncbi.nlm.nih.gov/pubmed/?term=25624257
14. https://www.ncbi.nlm.nih.gov/pubmed/?term=25643926
15. https://www.ncbi.nlm.nih.gov/pubmed/?term=25684680
16. https://www.ncbi.nlm.nih.gov/pubmed/?term=25704710
17. https://www.ncbi.nlm.nih.gov/pubmed/?term=25724133
18. https://www.ncbi.nlm.nih.gov/pubmed/?term=25762527
19. https://www.ncbi.nlm.nih.gov/pubmed/?term=25814186
20. https://www.ncbi.nlm.nih.gov/pubmed/?term=25841977
21. https://www.ncbi.nlm.nih.gov/pubmed/?term=25937213
22. https://www.ncbi.nlm.nih.gov/pubmed/?term=28094526
23. Chen, Xin; Mei, Yicheng; Yu, Aimin; Wang, Kaiwen. Improved method for preparation of resveratrol. Faming Zhuanli Shenqing Gongkai Shuomingshu (2007), 6pp.
24. Chen, Xin; Mei, Yicheng; Yu, Aimin; Wang, Kaiwen. Improved method for preparation of resveratrol. Faming Zhuanli Shenqing Gongkai Shuomingshu (2007), 6pp.
25. Olas B, Zbikowska HM, Wachowicz B, Krajewski T, Buczynski A, Magnuszewska A: Inhibitory effect of resveratrol on free radical generation in blood platelets. Acta Biochim Pol. 1999;46(4):961-6.
26. Vilar S, Quezada E, Santana L, Uriarte E, Yanez M, Fraiz N, Alcaide C, Cano E, Orallo F: Design, synthesis, and vasorelaxant and platelet antiaggregatory activities of coumarin-resveratrol hybrids. Bioorg Med Chem Lett. 2006 Jan 15;16(2):257-61. Epub 2005 Nov 3.
27. Niles RM, Cook CP, Meadows GG, Fu YM, McLaughlin JL, Rankin GO: Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr. 2006 Oct;136(10):2542-6.
28. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004 Sep-Oct;24(5A):2783-840.
29. Olas B, Nowak P, Wachowicz B: Resveratrol protects against peroxynitrite-induced thiol oxidation in blood platelets. Cell Mol Biol Lett. 2004;9(4A):577-87.
30. Kirk RI, Deitch JA, Wu JM, Lerea KM: Resveratrol decreases early signaling events in washed platelets but has little effect on platelet in whole blood. Blood Cells Mol Dis. 2000 Apr;26(2):144-50.
31. Olas B, Wachowicz B, Majsterek I, Blasiak J: Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and lymphocytes. Anticancer Drugs. 2005 Jul;16(6):659-65.
32. Anekonda TS: Resveratrol--a boon for treating Alzheimer's disease? Brain Res Rev. 2006 Sep;52(2):316-26.
33. Miksits M, Maier-Salamon A, Aust S, Thalhammer T, Reznicek G, Kunert O, Haslinger E, Szekeres T, Jaeger W: Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica. 2005 Dec;35(12):1101-19.
34. Chun YJ, Kim MY, Guengerich FP: Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun. 1999 Aug 19;262(1):20-4.
35. Gester S, Wuest F, Pawelke B, Bergmann R, Pietzsch J: Synthesis and biodistribution of an 18F-labelled resveratrol derivative for small animal positron emission tomography. Amino Acids. 2005 Dec;29(4):415-28. Epub 2005 Jul 8.
36. Fulda S, Debatin KM: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 2004 Jan 1;64(1):337-46.
37. Kimura Y, Okuda H: Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr. 2001 Jun;131(6):1844-9.
38. Gehm BD, McAndrews JM, Chien PY, Jameson JL: Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14138-43.
39. Bertelli AA, Giovannini L, Bernini W, Migliori M, Fregoni M, Bavaresco L, Bertelli A: Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res. 1996;22(2):61-3.
40. Delmas D, Rebe C, Lacour S, Filomenko R, Athias A, Gambert P, Cherkaoui-Malki M, Jannin B, Dubrez-Daloz L, Latruffe N, Solary E: Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem. 2003 Oct 17;278(42):41482-90. Epub 2003 Aug 5.
41. Yanez M, Fraiz N, Cano E, Orallo F: Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem Biophys Res Commun. 2006 Jun 2;344(2):688-95. Epub 2006 Apr 17.
42. Lee B, Moon SK: Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular smooth muscle cells. J Nutr. 2005 Dec;135(12):2767-73.
43. Aziz MH, Nihal M, Fu VX, Jarrard DF, Ahmad N: Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther. 2006 May;5(5):1335-41.
44. Zhuang H, Kim YS, Koehler RC, Dore S: Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann N Y Acad Sci. 2003 May;993:276-86; discussion 287-8.
45. Bass TM, Weinkove D, Houthoofd K, Gems D, Partridge L: Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech Ageing Dev. 2007 Oct;128(10):546-52. Epub 2007 Aug 14.
46. Ferrieres J: The French paradox: lessons for other countries. Heart. 2004 Jan;90(1):107-11.
47. Kopp P: Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol. 1998 Jun;138(6):619-20.